Immunomodulatory and clinical effects of receptor-interacting protein kinase 1 (RIPK1) inhibitor eclitasertib (SAR443122) in patients with severe COVID-19: a phase 1b, randomized, double-blinded, placebo-controlled study.

Respir Res · 2024 · PMC10903152 · PMID 38419035

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In the current study, the leukocyte count, neutrophil/lymphocyte ratio, and LDH level as well as plasma IL-6, IL-8 and IL-6/IL-10 showed a trend towards being lower in the eclitasertib than placebo group.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.